A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
← catalyst calendarNCT06561386 · readout in 1,441 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,000estimated
Sites
322
Countries
Argentina, Australia, Austria +28
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-07 | actual | When the study began enrolling |
| Primary completion | 2030-07-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-08-04 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer
Interventions
- Drug: Nivolumab
- Drug: Relatlimab
- Drug: Pembrolizumab
- Drug: Carboplatin
- Drug: Pemetrexed
- Drug: Cisplatin
Primary outcome
what the primary-completion date above is the date OFOverall survival (OS) in randomized participants with PD-L1 1% to 49%
measured Up to 5 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed